CorMedix (CRMD) Total Non-Current Liabilities (2013 - 2021)
CorMedix's (CRMD) quarterly Total Non-Current Liabilities came in at $6.0 million in Q4 2021, up 53.06% quarter-over-quarter from $3.9 million in Q2 2017.
CorMedix (CRMD) Total Non-Current Liabilities (2013 - 2021) Analysis & Trends
CorMedix has disclosed Total Non-Current Liabilities across 6 years of filings, most recently posting $6.0 million for Q4 2021.
- Total Non-Current Liabilities for Q4 2021 came in at $6.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2021 was $6.0 million (changed N/A YoY), and the FY2021 annual result was $6.0 million, changed N/A from the prior year.
- Total Non-Current Liabilities came in at $6.0 million for Q4 2021 at CorMedix, up from $3.9 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $6.0 million in Q4 2021 to a low of $3.9 million in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 64.76 Mn |
| 10 | CorMedix | 631,378.03 | -154.57 Mn | 107.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 5.98 Mn |
| Jun 30, 2017 | 3.91 Mn |
| Dec 31, 2016 | 4.09 Mn |
| Dec 31, 2015 | 3.09 Mn |
| Dec 31, 2014 | -3.63 Mn |
| Dec 31, 2013 | -1.29 Mn |